Park et al. (133) recently reported that Cer and glucosylceramide accumulate in the skeletal muscle of a senescent mouse model and that deleting serine palmitoyltransferase (SPT), the rate-limiting enzyme for sphingolipid biosynthesis, or using the SPT inhibitor myriocin to inhibit sphingolipid synthesis prevents sarcopenia and improves muscle health. Here, AGXT is linked to sarcopenia.